Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings
- PMID: 22132237
- PMCID: PMC3223235
- DOI: 10.1371/journal.pone.0028184
Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings
Abstract
Commercially available HIV-1 drug resistance (HIVDR) genotyping assays are expensive and have limitations in detecting non-B subtypes and circulating recombinant forms that are co-circulating in resource-limited settings (RLS). This study aimed to optimize a low cost and broadly sensitive in-house assay in detecting HIVDR mutations in the protease (PR) and reverse transcriptase (RT) regions of pol gene. The overall plasma genotyping sensitivity was 95.8% (N = 96). Compared to the original in-house assay and two commercially available genotyping systems, TRUGENE® and ViroSeq®, the optimized in-house assay showed a nucleotide sequence concordance of 99.3%, 99.6% and 99.1%, respectively. The optimized in-house assay was more sensitive in detecting mixture bases than the original in-house (N = 87, P<0.001) and TRUGENE® and ViroSeq® assays. When the optimized in-house assay was applied to genotype samples collected for HIVDR surveys (N = 230), all 72 (100%) plasma and 69 (95.8%) of the matched dried blood spots (DBS) in the Vietnam transmitted HIVDR survey were genotyped and nucleotide sequence concordance was 98.8%; Testing of treatment-experienced patient plasmas with viral load (VL) ≥ and <3 log10 copies/ml from the Nigeria and Malawi surveys yielded 100% (N = 46) and 78.6% (N = 14) genotyping rates, respectively. Furthermore, all 18 matched DBS stored at room temperature from the Nigeria survey were genotyped. Phylogenetic analysis of the 236 sequences revealed that 43.6% were CRF01_AE, 25.9% subtype C, 13.1% CRF02_AG, 5.1% subtype G, 4.2% subtype B, 2.5% subtype A, 2.1% each subtype F and unclassifiable, 0.4% each CRF06_CPX, CRF07_BC and CRF09_CPX.
Conclusions: The optimized in-house assay is broadly sensitive in genotyping HIV-1 group M viral strains and more sensitive than the original in-house, TRUGENE® and ViroSeq® in detecting mixed viral populations. The broad sensitivity and substantial reagent cost saving make this assay more accessible for RLS where HIVDR surveillance is recommended to minimize the development and transmission of HIVDR.
Conflict of interest statement
Figures

Similar articles
-
Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country.J Clin Microbiol. 2013 Feb;51(2):529-39. doi: 10.1128/JCM.02347-12. Epub 2012 Dec 5. J Clin Microbiol. 2013. PMID: 23224100 Free PMC article.
-
Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.J Clin Virol. 2007 Jun;39(2):125-31. doi: 10.1016/j.jcv.2007.03.008. Epub 2007 Apr 20. J Clin Virol. 2007. PMID: 17449318
-
Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance.J Clin Microbiol. 2010 Sep;48(9):3158-64. doi: 10.1128/JCM.00564-10. Epub 2010 Jul 21. J Clin Microbiol. 2010. PMID: 20660209 Free PMC article.
-
Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance.AIDS Rev. 2010 Oct-Dec;12(4):195-208. AIDS Rev. 2010. PMID: 21179184 Review.
-
The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance.Microb Genom. 2025 Mar;11(3):001375. doi: 10.1099/mgen.0.001375. Microb Genom. 2025. PMID: 40111248 Free PMC article. Review.
Cited by
-
The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.J Virol Methods. 2015 Oct;223:30-2. doi: 10.1016/j.jviromet.2015.07.005. Epub 2015 Jul 17. J Virol Methods. 2015. PMID: 26192603 Free PMC article.
-
Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.PLoS One. 2019 Nov 21;14(11):e0224292. doi: 10.1371/journal.pone.0224292. eCollection 2019. PLoS One. 2019. PMID: 31751353 Free PMC article.
-
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13.BMC Infect Dis. 2019 Sep 16;19(Suppl 1):787. doi: 10.1186/s12879-019-4339-y. BMC Infect Dis. 2019. PMID: 31526373 Free PMC article.
-
Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.Infect Dis (Auckl). 2017 Dec 19;10:1178633717749597. doi: 10.1177/1178633717749597. eCollection 2017. Infect Dis (Auckl). 2017. PMID: 29308013 Free PMC article. Review.
-
Human Immunodeficiency Virus Type-1 Genetic Diversity and Drugs Resistance Mutations among People Living with HIV in Karachi, Pakistan.Viruses. 2024 Jun 14;16(6):962. doi: 10.3390/v16060962. Viruses. 2024. PMID: 38932254 Free PMC article.
References
-
- Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22–32. - PubMed
-
- Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis. 2006;19:607–614. - PubMed
-
- Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, et al. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther. 2008;13(Suppl 2):49–57. - PubMed
-
- Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008;13(Suppl 2):15–23. - PubMed
-
- Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. PLoS One. 2008;13(Suppl 2):e4724. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials